Barinthus Biotherapeutics
Harwell
About Barinthus Biotherapeutics
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $215.6M
- Funding stage: M&A
- Last round: Series B (Mar 2021)
- Ticker: nasdaq:BRNS
- Website: barinthusbio.com
- Phone: +44 (0)1865 818808
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/barinthus-biotherapeutics-33260 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.